Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Dermatologic 3Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 344Rituximab 309Vincristine 159venetoclax 156Doxorubicin 156fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 110Dexamethasone 106Cytarabine 100ibrutinib 96Etoposide 94fludarabine phosphate 87Methotrexate 86acalabrutinib 80zanubrutinib 73Bendamustine Hydrochloride 72pembrolizumab 63blinatumomab 63CT-P10 61Gemcitabine 52glofitamab 45Nivolumab 45Calcium Dobesilate 45prednylidene 43Mercaptopurine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
vedolizumab × Lymphoid × 1 year × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡